



Epichem Awarded One-Year Contract Extension from DNDi

18 February 2019 – Perth, Australia: PharmAust Limited (ASX:PAA), a clinical-stage oncology company, is pleased to announce that its wholly owned subsidiary, Epichem Pty Ltd, has been awarded an extension to its current contract with Drugs for Neglected Diseases *initiative* (DNDi) (www.dndi.org).

The contract will see Epichem continue to provide synthetic and medicinal chemistry expertise to support DNDi's drug discovery projects, aimed at developing new treatments for neglected diseases, until 31st December 2019. The extension is expected to generate up to AUD\$1.24m in revenues for Epichem during 2019.

Epichem's CEO, Dr Martine Keenan said "We are delighted the contract with DNDi has been renewed. This will mark our 11th year with DNDi supporting their important work and we look forward to continuing our long-standing relationship with them."

PharmAust's Chairman Dr Roger Aston said "It is tremendous that Epichem have secured a further extension to this work with such a leading R&D organisation as DNDi".

Enquiries:

Dr Martine Keenan
CEO Epichem
Tel: 08 6167 5204
martine.keenan@epichem.com.au

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
raston@pharmaust.com

About Epichem:

Epichem is a wholly owned subsidiary of the ASX listed company PharmAust Limited. Located in Technology Park, Western Australia, Epichem has been delivering products and services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries in 35 countries worldwide for over 15 years. Epichem has a newly constructed state-of-the-art laboratory and has world class equipment and expertise in synthetic and medicinal chemistry for the cost-effective synthesis of drug analogue libraries and intermediates. It also has a rapidly growing catalogue of pharmaceutical reference standards. More information at www.epichem.com.au

About PharmAust (PAA):

PAA is a clinical-stage company developing targeted cancer therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract synthetic drug manufacturer which generated Aus\$3.02m in revenues in the 2018 FY.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway - a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs. MPL treatment was well-tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug into Phase 2 clinical trials.